Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12058
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLau, David Ken
dc.contributor.authorAndrews, Miles Cen
dc.contributor.authorTurner, Natalieen
dc.contributor.authorAzad, Arun Aen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorCebon, Jonathan Sen
dc.date.accessioned2015-05-16T01:42:13Z
dc.date.available2015-05-16T01:42:13Z
dc.date.issued2014-04-01en
dc.identifier.citationMelanoma Research; 24(2): 144-9en
dc.identifier.govdoc24463460en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12058en
dc.description.abstractWe studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)≥2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16%) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAntineoplastic Agents.adverse effects.therapeutic useen
dc.subject.otherDisease-Free Survivalen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherImidazoles.adverse effects.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherMelanoma.drug therapy.pathologyen
dc.subject.otherMiddle Ageden
dc.subject.otherNeoplasm Stagingen
dc.subject.otherOximes.adverse effects.therapeutic useen
dc.subject.otherPrognosisen
dc.subject.otherRetrospective Studiesen
dc.subject.otherSkin Neoplasms.drug therapy.pathologyen
dc.subject.otherTreatment Outcomeen
dc.titleA single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.en
dc.typeJournal Articleen
dc.identifier.journaltitleMelanoma researchen
dc.identifier.affiliationaLudwig Institute for Cancer Research - Austin Branch, Joint Ludwig-Austin Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Health bEastern Health Clinical School, Monash University, Victoria, Australiaen
dc.identifier.doi10.1097/CMR.0000000000000036en
dc.description.pages144-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24463460en
dc.type.austinJournal Articleen
local.name.researcherCebon, Jonathan S
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.